Aurobindo Pharma has received final approval from the United States Food and Drug Administration (USFDA) for its Dextromethorphan Polistirex Extended-Release Oral Suspension. The approved over-the-counter (OTC) formulation contains 30 mg of the active ingredient per 5 ml of suspension and is bioequivalent to the reference listed drug Delsym Extended-Release Oral Suspension.

Product Specifications and Market Details

The newly approved medication is designed to provide extended relief from cough symptoms. The following table outlines the key product and market details:

Manufacturing and Portfolio Impact

The product will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma. This approval brings the company's total ANDA approvals from USFDA to 580, comprising 557 final approvals and 23 tentative approvals.

The extended-release oral suspension temporarily relieves cough due to minor throat and bronchial irritation associated with common cold or inhaled irritants, and helps suppress the impulse to cough for better sleep.

Market Implications

With an estimated market size of US$ 138.00 million according to Nielsen data, this approval enables Aurobindo Pharma to enter a significant segment of the US cough medication market. The OTC nature of the product allows for broader market accessibility without prescription requirements, potentially contributing to the company's revenue growth from the American market.

Regulatory Significance

Receiving USFDA approval demonstrates that Aurobindo Pharma's manufacturing processes and product quality meet stringent American regulatory standards. The bioequivalence to the established reference drug Delsym further validates the therapeutic effectiveness of the company's formulation, strengthening its position in the competitive US pharmaceutical market.

Aurobindo Pharma 's biologics subsidiary TheraNym Biologics has announced the execution of an additional product schedule with Merck Sharp & Dohme Singapore Trading Pte. Ltd. (MSD), further expanding their existing contract manufacturing relationship. The development involves a significant greenfield manufacturing facility investment as disclosed under SEBI regulations.

Macquarie's Investment Outlook

Macquarie has maintained its Underperform rating on Aurobindo Pharma with a target price of ₹1,050. While the expanded biologics manufacturing deal with Merck validates the company's biologics capabilities, analysts expect meaningful financial upside only in 3-4 years as the facility ramps up operations.

Enhanced Partnership with Merck Sharp & Dohme

TheraNym Biologics has strengthened its collaboration with MSD by executing an additional product schedule that expands the existing CMO agreement initiated in May 2024. This latest development serves to further broaden the scope of their strategic partnership in biologics manufacturing.

Major Manufacturing Investment - Unit 2

Under the newly signed product schedule, TheraNym Biologics will construct a greenfield project for commissioning a large scale mammalian Drug Substance manufacturing facility designated as "Unit 2". The facility will house substantial bioreactor capacity with requisite downstream purification infrastructure.

Regulatory Compliance and Business Rationale

The company has made the disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. According to the regulatory filing, TheraNym will build the manufacturing facility, manufacture the products and supply to MSD as per the arrangement. The initiative aims to further expand the existing relationship in contract manufacturing operations for biologicals, strengthening the company's position in the growing biologics manufacturing sector.